These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35794889)

  • 1. COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.
    Wang L; Berger NA; Davis PB; Kaelber DC; Volkow ND; Xu R
    medRxiv; 2022 Jun; ():. PubMed ID: 35794889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 rebound after Paxlovid treatment during Omicron BA.5 vs BA.2.12.1 subvariant predominance period.
    Wang L; Volkow ND; Davis PB; Berger NA; Kaelber DC; Xu R
    medRxiv; 2022 Aug; ():. PubMed ID: 35982673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir.
    Parums DV
    Med Sci Monit; 2022 Oct; 28():e938532. PubMed ID: 36181334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir.
    Wong GL; Yip TC; Lai MS; Wong VW; Hui DS; Lui GC
    JAMA Netw Open; 2022 Dec; 5(12):e2245086. PubMed ID: 36472873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study.
    Han J; Bae S; Jung J; Kim MJ; Chong YP; Lee SO; Choi SH; Kim YS; Chang E; Kim SH
    Medicine (Baltimore); 2023 Sep; 102(39):e35094. PubMed ID: 37773854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paxlovid (nirmatrelvir/ritonavir) effectiveness against hospitalization and death in N3C: A target trial emulation study.
    Hansen K; Makkar SR; Sahner D; Fessel J; Hotaling N; Sidky H
    medRxiv; 2023 Jun; ():. PubMed ID: 37398261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
    Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
    JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients.
    Alteri C; Fox V; Scutari R; Burastero GJ; Volpi S; Faltoni M; Fini V; Granaglia A; Esperti S; Gallerani A; Costabile V; Fontana B; Franceschini E; Meschiari M; Campana A; Bernardi S; Villani A; Bernaschi P; Russo C; Guaraldi G; Mussini C; Perno CF
    Commun Biol; 2022 Dec; 5(1):1376. PubMed ID: 36522489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 10. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
    Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
    Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
    Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
    MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform.
    Zheng B; Green ACA; Tazare J; Curtis HJ; Fisher L; Nab L; Schultze A; Mahalingasivam V; Parker EPK; Hulme WJ; Bacon SCJ; DeVito NJ; Bates C; Evans D; Inglesby P; Drysdale H; Davy S; Cockburn J; Morton CE; Hickman G; Ward T; Smith RM; Parry J; Hester F; Harper S; Mehrkar A; Eggo RM; Walker AJ; Evans SJW; Douglas IJ; MacKenna B; Goldacre B; Tomlinson LA
    BMJ; 2022 Nov; 379():e071932. PubMed ID: 36384890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
    Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
    Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proxalutamide for the treatment of COVID-19 rebound following Paxlovid treatment: Report of four cases and review of the literature.
    Yang DW; Ju MJ; Wang H; Jia YC; Wang XD; Fang H; Fan J
    J Clin Lab Anal; 2023 Apr; 37(7):e24880. PubMed ID: 37088868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
    Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
    JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis.
    Wen W; Chen C; Tang J; Wang C; Zhou M; Cheng Y; Zhou X; Wu Q; Zhang X; Feng Z; Wang M; Mao Q
    Ann Med; 2022 Dec; 54(1):516-523. PubMed ID: 35118917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Schilling WHK; Jittamala P; Watson JA; Boyd S; Luvira V; Siripoon T; Ngamprasertchai T; Batty EM; Cruz C; Callery JJ; Singh S; Saroj M; Kruabkontho V; Ngernseng T; Tanglakmankhong N; Tubprasert J; Abdad MY; Madmanee W; Kouhathong J; Suwannasin K; Pagornrat W; Piaraksa N; Hanboonkunupakarn P; Hanboonkunupakarn B; Poovorawan K; Potaporn M; Srisubat A; Loharjun B; Taylor WRJ; Chotivanich V; Chotivanich K; Imwong M; Pukrittayakamee S; Dondorp AM; Day NPJ; Teixeira MM; Piyaphanee W; Phumratanaprapin W; White NJ;
    Lancet Infect Dis; 2024 Jan; 24(1):36-45. PubMed ID: 37778363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study.
    Qian G; Wang X; Patel NJ; Kawano Y; Fu X; Cook CE; Vanni KMM; Kowalski EN; Banasiak EP; Bade KJ; Srivatsan S; Williams ZK; Todd DJ; Weinblatt ME; Wallace ZS; Sparks JA
    medRxiv; 2022 Oct; ():. PubMed ID: 36324801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molnupiravir and risk of post-acute sequelae of covid-19: cohort study.
    Xie Y; Choi T; Al-Aly Z
    BMJ; 2023 Apr; 381():e074572. PubMed ID: 37161995
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.